首页> Journal of experimental & clinical cancer research : CR> First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.

First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.

导出 OA

翻译打印收藏纠错

第一作者： Christopher B,Cole

第一单位： Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

作者： Christopher B,Cole ^[1] ; Maria Pia,Morelli ^[1] ; Massimo,Fantini ^[2] ; Markku,Miettinen ^[3] ; Patricia,Fetsch ^[3] ; Cody,Peer ^[4] ; William D,Figg ^[4] ; Tyler,Yin ^[4] ; Nicole,Houston ^[1] ; Ann,McCoy ^[1] ; Stanley,Lipkowitz ^[1] ; Alexandra,Zimmer ^[1] ; Jung-Min,Lee ^[1] ; Miroslava,Pavelova ^[1] ; Erin N,Villanueva ^[1] ; Kathryn,Trewhitt ^[1] ; B Brooke,Solarz ^[1] ; Maria,Fergusson ^[1] ; Sharon A,Mavroukakis ^[5] ; Anjum,Zaki ^[5] ; Kwong Y,Tsang ^[5] ; Philip M,Arlen ^[5] ; Christina M,Annunziata ^[6]

作者单位： Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. ^[1] Precision Biologics, Inc, Bethesda, MD, USA. massimo.fantini@precision-biologics.com. ^[2] Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. ^[3] Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. ^[4] Precision Biologics, Inc, Bethesda, MD, USA. ^[5] Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. annunzic@mail.nih.gov. ^[6]

关键词 Antibody-dependent cellular cytotoxicity Cancer immunotherapy Clinical trial Monoclonal antibody NEO-201 O-glycan Regulatory T cells